Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CURR NASDAQ:EGHT NASDAQ:NRC NASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURRCurrenc Group$1.45-4.6%$0.83$0.33▼$7.08$67.47M-0.282.85 million shs545,344 shsEGHT8X8$1.93-1.5%$1.85$1.51▼$3.52$259.54M1.831.09 million shs598,501 shsNRCNational Research$14.22-4.9%$15.30$9.76▼$27.07$324M0.4589,789 shs77,099 shsOABIOmniAb$1.95-0.5%$1.65$1.22▼$4.96$238.16M0.14650,338 shs644,930 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURRCurrenc Group0.00%-7.64%+302.89%-5.84%+144,999,900.00%EGHT8X80.00%0.00%+4.89%+22.54%-33.90%NRCNational Research0.00%-10.90%-15.51%+34.91%-42.12%OABIOmniAb0.00%-3.94%+18.18%+8.94%-59.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCURRCurrenc GroupN/AN/AN/AN/AN/AN/AN/AN/AEGHT8X83.2734 of 5 stars3.03.00.00.02.52.51.9NRCNational Research2.492 of 5 stars0.04.01.70.01.82.51.3OABIOmniAb2.3283 of 5 stars3.51.00.00.00.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURRCurrenc Group 3.50Strong Buy$3.50141.38% UpsideEGHT8X8 2.00Hold$2.5130.27% UpsideNRCNational Research 0.00N/AN/AN/AOABIOmniAb 3.00Buy$7.00258.97% UpsideCurrent Analyst Ratings BreakdownLatest CURR, NRC, EGHT, and OABI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/27/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/20/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.70 ➝ $2.705/14/2025EGHT8X8B. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $3.005/12/2025OABIOmniAbBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.005/10/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.30 ➝ $2.704/22/2025EGHT8X8Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$2.00 ➝ $1.50(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURRCurrenc Group$43.39M1.55N/AN/A($0.90) per share-1.61EGHT8X8$715.07M0.36$0.65 per share2.95$0.93 per share2.08NRCNational Research$143.06M2.26$1.33 per share10.66$1.36 per share10.46OABIOmniAb$26.39M9.03N/AN/A$2.37 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURRCurrenc Group-$39.47MN/A0.00∞N/AN/AN/A-38.11%8/19/2025 (Estimated)EGHT8X8-$27.21M-$0.21N/A19.30N/A-3.81%5.73%0.90%N/ANRCNational Research$24.78M$1.0313.81∞N/A17.14%71.33%18.67%7/28/2025 (Estimated)OABIOmniAb-$62.03M-$0.58N/AN/AN/A-229.11%-21.37%-18.84%8/6/2025 (Estimated)Latest CURR, NRC, EGHT, and OABI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OABIOmniAb-$0.1517N/AN/AN/A$5.33 millionN/A5/20/2025Q1 2025CURRCurrenc Group-$0.04-$0.13-$0.09-$0.13$10.50 million$10.06 million5/8/2025Q1 2025OABIOmniAb-$0.17-$0.17N/A-$0.17$4.49 million$4.15 million4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCURRCurrenc GroupN/AN/AN/AN/AN/AEGHT8X8N/AN/AN/AN/AN/ANRCNational Research$0.483.38%N/A46.60%N/AOABIOmniAbN/AN/AN/AN/AN/ALatest CURR, NRC, EGHT, and OABI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/25/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURRCurrenc GroupN/A0.610.61EGHT8X82.771.201.20NRCNational Research1.980.540.54OABIOmniAbN/A4.704.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURRCurrenc Group56.01%EGHT8X893.99%NRCNational Research47.26%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipCURRCurrenc Group17.80%EGHT8X82.01%NRCNational Research8.10%OABIOmniAb8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURRCurrenc Group246.53 million38.25 millionN/AEGHT8X81,942134.48 million131.78 millionOptionableNRCNational Research49022.78 million20.94 millionOptionableOABIOmniAb7122.14 million111.63 millionOptionableCURR, NRC, EGHT, and OABI HeadlinesRecent News About These CompaniesOmniAb to Report Second Quarter 2025 Financial Results on August 6July 16, 2025 | businesswire.comPositive week for OmniAb, Inc. (NASDAQ:OABI) institutional investors who lost 47% over the past yearJuly 4, 2025 | finance.yahoo.comChairman of OmniAb Picks Up 3.0% More StockMay 19, 2025 | uk.finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Director Steven Love Purchases 25,000 SharesMay 15, 2025 | insidertrades.comInsider Buying: OmniAb, Inc. (NASDAQ:OABI) Director Buys 65,000 Shares of StockMay 14, 2025 | insidertrades.comOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston SummitMay 13, 2025 | businesswire.comIs OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comOmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOmniAb, Inc. (OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comOmniAb Introduces the xPloration® Partner Access ProgramMay 9, 2025 | tmcnet.comOmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comOmniAb Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comVERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid TumorsMay 5, 2025 | quiverquant.comQVERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramMay 5, 2025 | globenewswire.comCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comOmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesDollar Down 10%? These 3 Stocks Could SoarBy Chris Markoch | July 1, 2025View Dollar Down 10%? These 3 Stocks Could SoarQualcomm: Undervalued Chip Stock in Breakout UptrendBy Sam Quirke | July 17, 2025View Qualcomm: Undervalued Chip Stock in Breakout UptrendWhy Now Could Be the Smartest Time to Buy Crypto StocksBy Nathan Reiff | July 10, 2025View Why Now Could Be the Smartest Time to Buy Crypto StocksQualcomm’s Hold Rating Misses Strong Growth StoryBy Jeffrey Neal Johnson | July 4, 2025View Qualcomm’s Hold Rating Misses Strong Growth StoryCameco's 80% 3-Month Gain May Be Just the StartBy Jeffrey Neal Johnson | July 17, 2025View Cameco's 80% 3-Month Gain May Be Just the StartCURR, NRC, EGHT, and OABI Company DescriptionsCurrenc Group NASDAQ:CURR$1.45 -0.07 (-4.61%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.47 +0.02 (+1.66%) As of 07/18/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.8X8 NASDAQ:EGHT$1.93 -0.03 (-1.53%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.98 +0.05 (+2.54%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.8x8, Inc. engages in the provision of enterprise communication solutions. It offers solutions to the business services, education, financial services, government, healthcare, and manufacturing industries. The company was founded in February 1987 and is headquartered in Campbell, CA.National Research NASDAQ:NRC$14.22 -0.73 (-4.88%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.37 +0.15 (+1.08%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.OmniAb NASDAQ:OABI$1.95 -0.01 (-0.51%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.95 0.00 (0.00%) As of 07/18/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.